Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: TobagoJack who wrote (180432)	11/18/2021 8:39:43 AM
From: Julius Wong	1 Recommendation Recommended By Snowshoe Read Replies (2) \| Respond to of 218617

U.S. to acquire 10M doses of Pfizer's COVID-19 pill Paxlovid Nov. 18, 2021 7:01 AM ET Pfizer Inc. (PFE) By: Mamta Mayani, SA News Editor 2 Comments Alexandros Michailidis/iStock Editorial via Getty Images Pfizer (NYSE: PFE) announces an agreement with the U.S. government to supply 10M treatment courses of its investigational COVID-19 oral antiviral candidate, Paxlovid (PF-07321332; ritonavir), subject to regulatory authorization from the FDA. Under the terms of the agreement, the U.S. will acquire 10M treatment courses beginning later this year and concluding in 2022. PFE will receive $5.29B from the U.S. government, pending and contingent upon regulatory authorization. Pricing for Paxlovid is based on the principles of advance commitment, volume, equity, and affordability. Pfizer is seeking U.S. authorization of PAXLOVID; rolling submissions have also commenced in several countries, and the company will continue working to submit applications to regulatory agencies around the world. Recently, Barclays' analysts said that Paxlovid could add $15B-$22B to Pfizer 2022 revenue.